Omeros reported a net loss of $30.1 million, or $0.62 per share, in the first quarter of 2018 compared with a net loss of $15.1 million, or $0.34 per share, in 2017’s first quarter, according to a press release.
Revenues for the quarter, all from sales of Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution), were $1.6 million compared with $12.3 million in the first quarter of 2017.
The lower revenue was attributed to decreased ASC and hospital purchasing “following the scheduled loss of pass-through reimbursement status as of Jan. (Read more...)
Uncategorized